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Abstract
Vitamin D has been shown to have anti-angiogenic properties and to play a protective role in several types of
cancer, including breast, prostate and cutaneous melanoma. Similarly, vitamin D levels have been shown to be
protective for risk of a number of conditions, including cardiovascular disease and chronic kidney disease, as well
as numerous autoimmune disorders such as multiple sclerosis, inﬂammatory bowel diseases and type 1 diabetes
mellitus. A study performed by Parekh et al. was the ﬁrst to suggest a role for vitamin D in age-related macular
degeneration (AMD) and showed a correlation between reduced serum vitamin D levels and risk for early AMD.
Based on this study and the protective role of vitamin D in diseases with similar pathophysiology to AMD, we
examined the role of vitamin D in a family-based cohort of 481 sibling pairs. Using extremely phenotypically
discordant sibling pairs, initially we evaluated the association of neovascular AMD and vitamin D/sunlight-related
epidemiological factors. After controlling for established AMD risk factors, including polymorphisms of the genes
encoding complement factor H (CFH) and age-related maculopathy susceptibility 2/HtrA serine peptidase
(ARMS2/HTRA1), and smoking history, we found that ultraviolet irradiance was protective for the development of
neovascular AMD (p ¼ 0.001). Although evaluation of serum vitamin D levels (25-hydroxyvitamin D [25(OH)D])
was higher in unaffected individuals than in their affected siblings, this ﬁnding did not reach statistical signiﬁcance.
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538 # HENRY STEWART PUBLICATIONS 1479–7364. HUMAN GENOMICS. VOL 5. NO 6. 538–568 OCTOBER 2011Based on the relationship between ultraviolet irradiance and vitamin D production, we employed a candidate gene
approach for evaluating common variation in key vitamin D pathway genes (the genes encoding the vitamin D
receptor [VDR]; cytochrome P450, family 27, subfamily B, polypeptide 1 [CYP27B1]; cytochrome P450, family 24,
subfamily A, polypeptide 1 [CYP24A1]; and CYP27A1) in this same family-based cohort. Initial ﬁndings were then
validated and replicated in the extended family cohort, an unrelated case–control cohort from central Greece
and a prospective nested case–control population from the Nurse’s Health Study and Health Professionals
Follow-Up Studies, which included patients with all subtypes of AMD for a total of 2,528 individuals. Single point
variants in CYP24A1 (the gene encoding the catabolising enzyme of the vitamin D pathway) were demonstrated
to inﬂuence AMD risk after controlling for smoking history, sex and age in all populations, both separately and,
more importantly, in a meta-analysis. This is the ﬁrst report demonstrating a genetic association between vitamin
D metabolism and AMD risk. These ﬁndings were also supplemented with expression data from human donor
eyes and human retinal cell lines. These data not only extend previous biological studies in the AMD ﬁeld, but
further emphasise common antecedents between several disorders with an inﬂammatory/immunogenic component
such as cardiovascular disease, cancer and AMD.
Keywords: vitamin D, age-related macular degeneration
Introduction
Several biological processes/cellular pathways
involved in conditions such as cancer, cardiovascular
disease and type 1 diabetes have also been implicated
in the pathophysiology of the neovascular form of
age-related macular degeneration (AMD). AMD, a
disease characterised by the loss of ability to drive,
recognise faces and read, is the leading cause of
blindness in the US elderly population. Most promi-
nent among these shared disease-associated processes
is angiogenesis, the deﬁning hallmark of neovascular
AMD.
1–3 Additionally, immune cell involvement,
inﬂammation and oxidative stress have all been
associated with these diseases.
2,4–19
Vitamin D is a circulating steroid hormone which
is thought to be protective in a variety of cancers,
including breast, prostate and cutaneous mela-
noma.
20–23 Although classically associated with
bone mineralisation and the regulation of Ca
2þ and
phosphorus (Pi),
24 vitamin D has been demonstrated
to have anti-angiogenic and anti-inﬂammatory
effects.
25–28 In addition, it has been shown to play a
role in cellular proliferation, differentiation and
apoptosis, as well as protecting cell proteins and
membranes from oxidative damage.
20,29,30
Vitamin D synthesis and metabolism begins
upon cutaneous ultraviolet (UV) B exposure,
resulting in the conversion of 7-dehydrocholesterol
to vitamin D. In addition to UVB, sources of
vitamin D include diet and supplements.
20 In the
liver, cytochrome P450, family 27, subfamily B,
polypeptide 1 (CYP27B1) catalyses the conversion
of vitamin D to its pro-hormonal major circulating
form, 25-hydroxyvitamin D (25(OH)D).
CYP27A1 then converts 25(OH)D to the biologi-
cally active form of vitamin D [1,25(OH)2D3].
31
The biologically active form of vitamin D binds to
the nuclear hormone receptor vitamin D receptor
gene (VDR). VDR heterodimerises with retinoid
X receptor alpha to regulate transcription by
binding vitamin D response elements in gene pro-
moters and recruiting transcriptional co-factors.
32
The active form of vitamin D is eventually catabo-
lised after processing in the kidney or liver by cyto-
chrome P450, family 24, subfamily A, polypeptide
1( CYP24A1).
33 Parekh et al. demonstrated an
inverse relationship between serum vitamin D
levels and early AMD but could not extrapolate the
ﬁndings to advanced AMD, potentially owing to
the small number of patients studied in this cat-
egory (n ¼ 10).
34 Based on this association and the
involvement of vitamin D in processes underlying
several diseases with an inﬂammatory or immune
component, we hypothesised that vitamin D might
play a role in AMD pathophysiology and, in par-
ticular, neovascular AMD. A special focus was
placed on neovascular AMD, as it is the advanced
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cases of severe vision loss and it is necessarily pre-
ceded by an early form of the disease. To evaluate
comprehensively the contribution of vitamin D
and vitamin D pathways to neovascular AMD and,
moreover, all subtypes of AMD, we conducted epi-
demiological, biological and genetic studies initially
on a family-based cohort. This was followed by
replication and validation of signiﬁcant genetic
ﬁndings in an unrelated case–control cohort from
central Greece, as well as two prospective cohorts
comprising AMD cases and controls from the
Nurse’s Health Study (NHS) and Health
Professionals Follow-Up Studies (HPFS).
An epidemiological study was conducted to
determine the association of dietary supplements,
UV light and sun-related variables, including iris
colour, self-reported sun exposure and skin cancer
history, with neovascular AMD. Serum levels of
vitamin D were also examined to assess further the
contribution of vitamin D levels to advanced AMD
risk. To assess if genetic variation within vitamin D
metabolism genes might be associated with neovas-
cular AMD, tagging single nucleotide polymorph-
isms (SNPs) within the vitamin D pathway genes
CYP27B1, CYP27A1, CYP24A1 and VDR were
genotyped to ﬁnd signiﬁcantly associated AMD risk
variants and haplotypes within a discovery cohort
comprising extremely discordant sibling pairs —
that is, where one sibling, the index patient, has the
neovascular form of AMD and the other sibling has
no signs of AMD and is older than 65 years of age.
Moreover, CYP27B1, CYP27A1, CYP24A1 and
VDR were chosen because they are vitamin D
pathway genes that are located in genomic regions
previously implicated in AMD disease suscepti-
bility.
35,36 Based on ﬁndings of genetic association
within this extremely discordant sibpair discovery
cohort, we replicated and validated ﬁndings in our
other cohorts as described below.
Material and methods
Family-based patient population
The protocol was reviewed and approved by the
Institutional Review Boards at the Massachusetts
Eye and Ear Inﬁrmary (MEEI), Boston, MA, USA,
and conformed to the tenets of the Declaration of
Helsinki. Eligible patients were enrolled in this
study after giving informed consent and before
completing a standardised questionnaire and donat-
ing 10–50 ml of venous blood.
Details of the recruitment of the sibling pairs,
comprising mainly individuals of European ancestry,
are described in detail elsewhere.
37,38 Brieﬂy, the
disease status of every participant was conﬁrmed by
at least two investigators by evaluation of fundus
photographs or ﬂuorescein angiograms, except
when one of the investigators directly examined an
unaffected sibling during a home visit (n ¼ 4 cases).
All index patients were approximately 50 years of
age or older and had the neovascular form of AMD
in at least one eye, deﬁned by subretinal haemor-
rhage, ﬁbrosis or ﬂuorescein angiographic presence
of neovascularisation. Patients whose only exudative
ﬁnding was a retinal pigment epithelium (RPE)
detachment were excluded because this ﬁnding
may not represent deﬁnite neovascular AMD.
Patients with signs of pathological myopia, pre-
sumed ocular histoplasmosis syndrome, angioid
streaks, choroidal rupture, any hereditary retinal
diseases other than AMD, and previous laser treat-
ment due to retinal conditions other than AMD
were also excluded.
Patients with an early/intermediate form of dry
AMD were classiﬁed according to the Age-Related
Eye Disease Study (AREDS)
39 as either category 2
(small [,63 mm] drusen with total area  125 mm,
or at least one intermediate druse [ 63 and
,125 mm], or presence of pigment abnormalities);
or AREDS category 3 (intermediate drusen com-
prising total area  360 mm in the presence of soft
drusen, or  656 mm in the absence of soft drusen,
or at least one large druse [ 125 mm], or non-
central geographical atrophy), as previously
described for this cohort.
40
The unaffected siblings had normal maculae and
were aged at least 65 years or older at the time at
which the index patient was ﬁrst diagnosed with
neovascular AMD. These criteria were based on
published epidemiological studies that indicated
that elderly individuals with such maculae rarely go
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follow-up.
41 Unaffected maculae fulﬁlled the fol-
lowing criteria: 0–5 small drusen (all less than
63 mm in diameter), no pigment abnormalities, no
geographical atrophy and no neovascularisation (as
deﬁned previously; AMD ‘category 1 or less’ on
the AREDS scale
39).
Replication cohorts
Replication of signiﬁcant ﬁndings was performed
on three unrelated case–control cohorts. The
central Greece cohort (as previously described
40)
included patients without AMD (controls; n ¼
198), with early and intermediate dry AMD
(AREDS category 2 and 3; n ¼ 84) and with neo-
vascular AMD (n ¼ 139) (Table S1). These patients
were recruited from the medical retina outpatient
clinic at the University Hospital of Larissa, Greece.
The diagnosis of macular degeneration was con-
ﬁrmed by optical coherence tomography and ﬂuor-
escein angiography. Colour fundus photography and
indocyanine green angiography were performed in
some cases.
A second replication cohort was a prospective,
nested case–control sample of participants from
two cohorts: the NHS and HPFS. Details of these
studies and ascertainment of AMD cases have been
previously described.
40,42,43 This combined NHS/
HPFS AMD cohort contained 1,527 individuals,
including 293 with the early or dry form of AMD
(AREDS category 2 and 3) and associated vision
loss to 20/30 or worse, 164 with the neovascular
form of the disease (AREDS category 4) and 1,070
age-matched controls who remained free of AMD
during the follow-up period (Table S1).
Epidemiological data
Data were obtained by conducting telephone or
in-person interviews to complete a standardised ques-
tionnaire. Data included iris colour as blue (light),
green (medium) or brown (dark). The regular use of
multivitamins or vitamin D supplements was ascer-
tained if supplements were taken at least twice a week
for at least six months prior to the index patient’s
diagnosis of AMD. Smoking data, as measured in
pack years (as described previously
37), was available
for every participant. Brieﬂy, a smoker was deﬁned as
smoking  10 pack-years and a non-smoker as
smoking less than 10 pack-years in their lifetime.
To quantify sunlight exposure, average UV radi-
ation (UVR) exposure was calculated for the
location at which each subject lived for the
majority of his or her lifetime on 133 sibpairs, for a
total of 276 individuals. Latitude, longitude and
elevation for each city and state were determined
using the website http://www.topozone.com.
Using the calculated longitude (range, 2123.03–
63.19), latitude (range, 25.99–46.49) and elevation
(range, 0.001–1.598 km) for each participant’s city
and state, UVR exposure was obtained using the
tropospheric UV-visible (TUV) calculator found at
the website http://cprm.acd.ucar.edu/Models/
TUV/Interactive_TUV/, using input option 1:
latitude and longitude, and output 2: irradiance,
weighted. The TUV calculator uses a model that
corrects for the effects of cloud cover, based on
data collected from November 1978 to June 2000,
as described on the website. UVR index and UV A
and UVB irradiances were reported in watts/m
2 for
noon on the 15th of each month for the year 2006
in order to assess UVexposure throughout the year.
Additionally, UV measures were taken on two
speciﬁc dates: summer solstice and winter solstice,
as these two days may have different UVexposures,
being the longest and shortest days of the year,
respectively. Yearly UV exposure was calculated as
the average of all the recorded exposures.
To validate our ﬁndings of association between
UVexposure and AMD, we obtained additional UV
data on our family-based cohort from a separate
source. The monthly average UV index was deter-
mined using the website for the US Environmental
Protection Agency’s SunWise Program (http://
www.epa.gov/sunwise1/doc/uvimonth.html). The
website reports average monthly exposure in terms
of UV index, based on data from the years
1994–2008. Yearly exposure was calculated by
averaging monthly exposures obtained for the
location at which each subject lived for the majority
of their lifetime.
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account for cumulative sun exposure. Self-reported
sun exposure was recorded for both current and —
separately — 15 years ago, as one of four categories:
(i) spends most of the day outside; (ii) spends most
free time outside; (iii) occasionally spends a day in
the sun; or (iv) almost never outside.
Measurement of circulating vitamin D
For the collection of sera, non-fasting blood was
drawn from 50 sibling pairs (100 subjects) in the
discovery cohort of extremely discordant sibling
pairs. Blood was collected into BD Vacutainer SST
tubes (BD, Franklin Lakes, NJ, USA) and samples
were centrifuged at room temperature (approxi-
mately 208C) at 1500 g for 10 minutes. Serum was
immediately drawn off and stored at 2808Ci n
2.0 ml cryogenic tubes (Corning Life Sciences,
Lowell, MA, USA).
Levels of circulating 25(OH)D were measured
in ng/ml, according to previously described
methods.
44 Patients were classiﬁed as deﬁcient if
serum 25(OH)D was less than 20 ng/ml; as insufﬁ-
cient if levels were between 21 and 29 ng/ml;
and as sufﬁcient if levels were between 30 and
150 ng/ml.
24 Serum 25(OH)D levels greater than
150 ng/ml were classiﬁed as toxic.
RPE–choroid expression proﬁle assessment
Whole-transcriptome expression proﬁles were avail-
able from 126 RPE–choroid and 118 retina
punches (each 6 mm in diameter) collected from
the macular and extramacular regions of eyes
derived from 66 human donors. These eyes were
selected from a well-characterised repository
derived from 3,903 donors and collected by G.S.H.
over a 20-year period at the University of Iowa and
St Louis University. Medical and ophthalmic his-
tories, a family questionnaire and blood and sera
were obtained from the majority of donors. Gross
pathological features, as well as the corresponding
fundus photographs and angiograms (when avail-
able) of all eyes in this repository were read and
classiﬁed by retinal specialists. Fundi and/or pos-
terior poles were graded using a slightly modiﬁed
version of two standardised classiﬁcation systems, as
published previously.
4,5,45–47 The ages of the
donors ranged from nine to 101 years; approxi-
mately 50 per cent had documented clinical his-
tories of AMD. RNA expression proﬁles were
assessed using two-colour, 44 K Agilent whole-
genome in situ oligonucleotide microarray analysis
and a universal reference RNA experimental
design. The universal reference RNA consisted of a
1:1 pool of RPE–choroid and retinal RNA gener-
ated from donors with and without AMD. After
correcting for dye effects using Lowess normalisa-
tion, the net intensity values were determined and
expressed as a percentage of the total array intensity.
The ratios of the experimental and reference RNA
signals were then calculated and the normalised
percentage total of each experimental value was
calculated by multiplication, using the geometric
mean of all determinations of each probe’s refer-
ence RNA value. For those probes with replicates
in the array, the average values were determined.
Inter-array differences were further corrected by
quantile normalisation and probes that did not have
net intensity values greater than six times the stan-
dard deviation of the background in at least 5 per
cent of the samples were omitted. This resulted in a
ﬁnal dataset comprising 28,127 unique probes.
Expression of the vitamin D pathway-associated
genes VDR, CYP27A1, CYP27B1 and CYP24A1
was examined.
Investigation of vitamin D in human retinal
cells
To investigate vitamin D signalling in retinal cells,
vitamin D was applied to retinoblastoma cells as a
ﬁrst iteration. Expression levels of mRNA were
compared between untreated and treated cells by
quantitative real-time polymerase chain reaction
(qRT-PCR) analysis. Weri-RB1 (American Type
Culture Collection [ATCC] catalogue number
HTB 169) and Y79 (ATCC catalogue number
HTB 18) were utilised for cell culture and sub-
sequent treatment with vitamin D3. Cells were cul-
tured in accordance with the manufacturer’s
speciﬁcation/requirements. Cells were treated with
10 mM Vitamin D3 (ﬁnal concentration) for 1
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Following the allotted treatment time, cells were
then harvested. RNA isolated from these cells was
used for qRT-PCR assays. For each gene tested,
three technical replicates were used, with 1 mlo f
cDNA being used in each well, with 5 mlo f
SYBR
w Green master mix (Invitrogen Corporation
Carlsbad, CA, USA), 3 mld H 20 and 1 mlo fa
forward/reverse mix of primers for a ﬁnal primer
concentration of 1 mM. The ﬁnal reaction volume
for each sample was 10 ml. Samples were run using
an ABI 9600 platform (Life Technologies Corp,
Carlsbad, CA, USA), for a total of 40 cycles, with
readings being taken every cycle. Triplicates were
averaged and the delta-Ct, compared with b-actin,
was determined for each gene. Each triplicate reac-
tion was performed for three separate RNA
samples. Standard deviation was calculated for each
dataset. Comparisons between time points and con-
trols were made for fold-change estimation and
relative expression, using the following formula:
1000/2
Delta-CtBactin-Delta-Cttestgene.
Genotyping analysis
Genotyping was performed on leukocyte DNA that
was puriﬁed by using standard phenol–chloroform
or DNAzol (Invitrogen) extraction protocols.
Initially, genotyping was performed with tagging
SNPs (tagSNPs) from the vitamin D pathway genes
CYP27A1, CYP27B1, VDR and CYP24A1.T h e s e
particular genes were chosen because they are in
regions of the genome previously reported by
linkage studies to harbour AMD susceptibility
loci.
36,48 CYP27A1 is located on chromosome
2q33-qter and spans approximately 34 kilobases (kb).
CYP27B1 is located on chromosome 12q13.1-q13.3
and spans approximately 5 kb. VDR is located on
chromosome 12q13.11 and spans 63 kb. CYP24A1
is located on chromosome 20q13 and spans approxi-
mately 21 kb. To assess variation within these genes,
tagSNPs were chosen to span each gene using data
from HapMap (http://www.hapmap.org/) and the
following criteria: (i) the minor allele frequency was
greater than 10 per cent; (ii) the r
2 value was at least
0.8; and (iii) SNPs tagged for at least six other
SNPs. The location of SNPs with respect to
introns/exons was analysed in terms of the largest
coding transcript for each gene, as listed in Ensembl
(http://www.ensembl.org/index.html) (Table S2).
These SNPs were supplemented with additional
SNPs, chosen to be evenly spaced along the length
of the gene in an effort fully to capture variation
within a given gene. In total, 59 SNPs were initially
screened by Sequenom (San Diego, CA, USA) in
the extremely discordant sibling pair discovery
cohort (135 sibling pairs, 270 individuals):
CYP27A1, n ¼ 4; VDR, n ¼ 33; CYP27B1, n ¼ 2;
CYP24A1, n ¼ 20 (Table S2).
Multiplex PCR assays were designed using
Sequenom SpectroDESIGNER software (version
3.0.0.3) by inputting sequence containing the SNP
site and 100 base pairs (bp) of ﬂanking sequence on
either side of the SNP . Brieﬂy, 10 ng of genomic
DNAwas ampliﬁed in a 5 ml reaction containing 1  
HotStar Taq PCR buffer (Qiagen, Valencia, CA,
USA), 1.625 mM MgCl2,5 0 0 mle a c hd N T P ,
100 nM each PCR primer and 0.5 U HotStar Taq
(Qiagen). The reaction was incubated at 948Cf o r1 5
minutes, followed by 45 cycles at 948Cf o r2 0
seconds, 568C for 30 seconds and 728C for 1 minute,
followed by another 3 minutes at 728C. Excess
dNTPs were then removed from the reaction mixture
by incubation with 0.3 U shrimp alkaline phospha-
tase (USB Corporation, Cleveland, OH, USA) at
378C for 40 minutes, followed by 5 minutes at 858C
to deactivate the enzyme. Single primer extension
over the SNP was carried out in a ﬁnal concentration
of between 0.625 mMa n d1 . 5mM for each extension
primer (depending on the mass of the probe), iPLEX
termination mix (Sequenom) and 1.35 U iPLEX
enzyme (Sequenom) and cycled using a two-step 200
short cycles programme; 948C for 30 seconds, fol-
lowed by 40 cycles at 948C for 5 seconds, ﬁve cycles
at 528Cf o r5s e c o n d s ,8 0 8C for 5 seconds and then
728C for 3 minutes. The reaction was then desalted
by the addition of 6 mg cation exchange resin, fol-
lowed by mixing and centrifugation to settle the con-
tents of the tube. The extension product was then
spotted onto a 384-well SpectroCHIP before being
ﬂown in the matrix-assisted laser desorption/ionis-
ation time-of-ﬂight (MALDI-TOF) mass spec-
trometer. Data were collected, in real time, using
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3.3.1.1 and SpectroCALLER 3.3.0.14 (Sequenom).
Additionally, to ensure data quality, genotypes for
each subject were checked manually.
In order to discover novel variation, a combi-
nation of direct sequencing and NextGen exon
capture were performed. Oligonucleotide primers
were selected using the Primer3 program (http://
primer3.sourceforge.net/) to encompass the SNP
and ﬂanking sequences (Table S3). All PCR assays
were performed using genomic DNA fragments
from 20 ng of leukocyte DNA in a solution of
10  PCR buffer containing 25 mM MgCl2,
0.2 mM each of dATP , dTTP , dGTP and dCTP ,
and 0.5 units of Taq DNA polymerase (USB). 5 M
betaine was added to the reaction mix for
rs2414687 (Sigma-Aldrich, St Louis, MO, USA).
The temperatures used during the PCR were as
follows: 958C for 5 minutes followed by 35 cycles
of 588C for 30 seconds, 728C for 30 seconds and
958C for 30 seconds, with a ﬁnal annealing at
588C for 1.5 minutes and extension of 728C for 5
minutes. For sequencing reactions, PCR products
were digested according to the manufacturer’s pro-
tocol using ExoSAP-IT (USB) and were then sub-
jected to a cycle sequencing reaction using the Big
Dye Terminator v3.1 Cycle Sequencing kit
(Applied Biosystems, Foster City, CA, USA),
according to the manufacturer’s protocol. Products
were puriﬁed using Performa DTR Ultra 96-well
plates (Edge Biosystems, Gaithersburg, MD, USA)
in order to remove excess dye terminators. NextGen
sequencing was performed on exonic regions using
methods that have been previously described.
49 For
direct sequencing, samples were sequenced on an
ABI Prism 3100 DNA sequencer (Applied
Biosystems). Electropherograms generated from the
ABI Prism 3100 were analysed using the Lasergene
DNA and protein analysis software (DNASTAR,
Inc., Madison, WI, USA). Electropherograms were
read by two independent evaluators without knowl-
edge of the subject’s disease status. All patients were
sequenced in the forward direction (50 to 30), unless
variants or polymorphisms were identiﬁed, in
which case conﬁrmation was obtained in some cases
by sequencing in the reverse direction.
For the genotyping of the variation discovered
by direct and NextGen sequencing, a combination
of direct sequencing and Taqman genotyping was
employed to supplement data previously acquired
by Sequenom or to investigate further variation.
Direct sequencing was used to genotype the
rs6022993, rs6091828, rs6127119, c.990 þ 189
G . A, rs6127118 and c.990 þ 222_223ins99
SNPs using a single set of primers: forward primer
TGGACTGAGGTTTTCTTCTGTG and reverse
primer GGCACATGAAGTCTCCTCCT. For all
other SNPs, Taqman genotyping was employed.
Brieﬂy, either TaqMan Pre-Designed SNP
Genotyping Assays or Custom TaqMan SNP
Genotyping Assays kits (Applied Biosystems) were
designed (for listing of SNPs and probes, see
Table S4). The 40  stock of the probes were
diluted to 16  with 0.5  tris-ethylenediamine
tetra-acetic acid (EDTA) and stored at 2208C. The
ampliﬁcation reaction was carried out in a total
reaction volume of 16.25 ml containing 2.5 ml
DNA (10 ng), 1.25 mlo f1 6   probe and 12.5 ml
of TaqMan Genotyping Master Mix. Sample DNA
was ampliﬁed using the following reaction: 1
minute at 608C, 10 minutes at 958C and 40 cycles
of 15 seconds at 928C and 1 minute at 608C. The
ampliﬁcation reaction was carried out on thermo-
cyclers and then ﬂuorescence was measured on the
ABI 7500 Real-Time PCR System by which the
genotypes are analysed with the accompanying
software or, in some cases, manually.
Statistical analysis
Epidemiological data
Conditional logistic regression (CLR) (SAS 9.0,
SAS Institute Inc., Cary, NC, USA) was performed
to identify factors associated with neovascular AMD.
Potential risk factors of interest, as deﬁned above,
were evaluated initially in single factor analysis.
Numerical variables such as serum 25(OH)D levels
and UV irradiance were tested as continuous vari-
ables, while other variables—including iris colour,
skin cancer history, self-reported sun exposure and
vitamin supplementation—were treated as categori-
cal. In addition to smoking, known genetic risk
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controlled for.
38,50–52 For these genetic variables,
each SNP (n ¼ 18) was tested under an additive
genetic model, along with UV irradiance. The
backward selection procedure in conditional logistic
regression was used to create the most parsimonious
statistical model predictive of neovascular AMD.
Speciﬁcally, each variable was tested for its associ-
ation with AMD and entered into the model if its
p-value was less than 0.15. Those variables that met
these criteria were then kept in the model if the
covariate-adjusted p-value was less than 0.1. Using
the variables selected in backward selection, a mul-
tiple variable model was constructed and tested for
its association with neovascular AMD.
Genotyping data
SNPs were tested for association using the minor
allele, as deﬁned by the allele occurring less
frequently in the normal subjects for all cohorts
examined. Initial testing of association between the
variation and AMD in the extremely discordant
sibling pair was done using the family-based associ-
ation test (FBAT) (http://biosun1.harvard.edu/~fbat/
fbat.htm) and generalised estimating equations
(GEE), assuming an additive genetic model in SAS.
For validation in the extended sibling cohort, allelic
associations were performed in SAS (v9.1) using con-
ditional logistic regression (CLR). For replication in
the unrelated case–control cohorts, allelic associations
were performed using unconditional logistic
regression (UCLR) in SAS. Both analyses were per-
formed assuming an additive genetic model and con-
trolling for covariates (age, sex and smoking). All
haplotypic associations were performed initially using
FBAT in the discovery cohort and then for validation
and replication using the program UNPHASED
(http://www.mrc-bsu.cam.ac.uk/personal/frank/
software/unphased/). For the family data, the model
for sibships was used. UNPHASED uses likelihood
ratio association analysis, and for sibships uses nuclear
families with missing parental genotype data.
53
Covariates—speciﬁcally age, sex and smoking
history—were controlled for in analysis using
residuals, as calculated in R Statistical Software
(http://www.r-project.org/).
Linkage disequilibrium (LD) (D0 and r
2) between
each of the SNPs was determined using
Haploview (http://www.broad.mit.edu/mpg/hap-
loview/). Deviation from Hardy–Weinberg
equilibrium was tested on each SNP using the
chi-square test in the unaffected population.
Haplotype blocks were constructed in Haploview
using the method proposed by Gabriel et al.
54
Haplotype blocks deﬁned by the Gabriel rule were
tested for association with all subtypes of AMD
using UNPHASED, and additionally FBAT in the
families. In addition to the use of residuals, multiple
testing in FBATwas corrected for using the permu-
tation test. Haplotype testing was also performed by
two additional methods, backward selection and
sliding window. Backward selection was performed
in UNPHASED, beginning with all SNPs with
association p value   0.12 in the model and taken
out one at a time in order to determine the most
signiﬁcantly parsimonious haplotype.
55 Sliding
window analysis was also performed in
UNPHASED, using a window size of 2 and using
all SNPs with association p   0.12. Genotype and
allele frequencies for all SNPs identiﬁed as either
individually signiﬁcant or signiﬁcant as part of a
haplotype were calculated in the affected patients
and separately in unaffected controls (Table S4).
Based on the variation found within the
extended sibling cohort, replication was performed
on a cohort of unrelated cases and controls from
central Greece and the combined NHS and HPFS
cohort. Meta-analysis of all four cohorts was
performed for SNPs genotyped in all four
cohorts and also signiﬁcant haplotypes using
the Comprehensive Meta-Analysis v2 (Biostat,
Englewood NJ, USA) program. Z-scores and
overall p-values for each SNP were calculated under
a ﬁxed model based on odds ratios obtained from
CLR for the family-based cohorts and UCLR for
the case-control cohorts calculated in SAS while
controlling for the covariates age, sex and smoking
history. To test for the effects of population hetero-
geneity, Cochran’s Q was also calculated, which is
the weighted sum of squared differences between
individual study effects and the pooled effect across
studies.
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the genes investigated here and previously reported
AMD-associated genes, an interaction term was
added into the regression model, including both vari-
ables. SNPs included in statistical analyses were SNPs
that had been genotyped in more than one cohort:
VDR (rs2189480); CFH (rs572515 and
rs1061170); ARMS2/HTRA1 (rs10490924,
rs11200638 and rs1049331); and RAR-related
Orphan receptor A gene (RORA; rs12900948 and
rs4335725).
38,40,42,51,52 An additional pooled case-
only analysis was performed in logistic regression to
test for interaction with greater power. Statistical
interaction was also tested for between UV measures
and the variants examined using an interaction term
in the regression models.
Bioinformatic analysis of functional
implications of genetic variants
Variants were analysed by computational methods to
infer potential functional relevance. Conservation
analysis was performed using the comparative geno-
mics feature in Ensembl (http://useast.ensembl.org/
index.html) to compare the human variant with
nine eutherian mammals, including chimp, mouse
and pig. To analyse the putative biological effects of
each exonic or intronic variation, either the major
or minor allele was input into predictive programs
ﬂanked on either side by 100 bp of sequence.
Potential human transcription factor binding sites
were analysed using default parameters of the tran-
scription element search system from the University
of Pennsylvania (http://www.cbil.upenn.edu/
cgi-bin/tess/tess). Additional analysis of putative
splice sites was performed using the default par-
ameters of the Alternative Splice Site Predictor
(http://www.es.embnet.org/~mwang/assp.html).
Also, the publicly available program mRNA by
SNP Browser v 1.0.1
56,57 was used to investigate
the association of signiﬁcant CYP24A1 SNPs and
expression quantitative trait loci (eQTLs).
Pathway analyses
We used Ingenuity Pathway Analysis (IPA) software
(http://www.ingenuity.com/) to create a visual
representation of the complex shared pathways
involved in the aetiology of AMD, the metabolism/
synthesis of vitamin D and the vascularisation pro-
cesses. The likelihood that each gene/protein is
randomly associated with a given function, pathway
or other protein/gene is automatically calculated
using the right-tailed Fisher’s exact test. We
accepted only those relationships with p . 0.0001,
suggesting that their association with our gene/
protein functions or diseases was non-random.
Results
Patient population
For our initial discovery cohort, we recruited a
total of 135 extremely discordant sibling pairs (one
sibling with neovascular AMD and one unaffected
sibling — AREDS category 1 or less). The
mean+SD age of the unaffected siblings was
76.0+7.6 years (age range, 50.3–93.9) and the
mean+SD of the affected (neovascular) siblings
was 71.7+8.0 years (age range, 49.0–86.5)
(Table S1). Of the affected patients, 47 per cent
were male and 39 per cent of the matching unaf-
fected siblings were male. Most participants were of
European descent.
The expanded sibling cohort comprised 481
sibling pairs and 657 individuals: 198 unaffected
controls, 106 early and intermediate dry AMD
patients (AREDS category 2 and 3), and 353 neo-
vascular AMD patients (Table S1). The mean+SD
age of the unaffected subjects was 75.4+8.3 years
(age range, 50.3–94.3 years), the mean age of the
patients with early or intermediate AMD was
77.6+7.2 years (age range, 58.2–100.6 years), and
the age of those subjects with neovascular AMD
was 73.9+7.8 years (age range, 49.0–94.0 years).
Forty-four percent of the unaffected subjects, 35
per cent of the AREDS category 2 and 3 AMD
subjects and 41 per cent of the neovascular subjects
were male. The cohort from central Greece con-
sisted of a total of 344 patients: 121 unaffected con-
trols, 84 early and intermediate dry AMD patients
(AREDS category 2 and 3) and 139 neovascular
AMD patients (Table S1). The mean+SD age of
the unaffected subjects was 73.5+7.3 years (age
range, 48.0–88.0 years), the age of the patients
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years (age range, 52.0–91.0 years) and the mean
age of those subjects with neovascular AMD was
76.2+7.5 years (age range, 49.0–94.0 years).
Fifty-one per cent of the unaffected subjects, 44
per cent of the AREDS category 2 and 3 AMD
subjects and 45 per cent of the neovascular subjects
were male. All participants were white and from
central Greece.
The prospective cohorts from the NHS and
HPFS consisted of a total of 1,527 patients: 1,070
unaffected controls, 293 early and intermediate dry
AMD patients (AREDS category 2 and 3) and 164
AMD neovascular patients. The mean+SD age of
the unaffected subjects was 60.2+5.9 years (age
range, 41.3–74.0 years), the age of the patients with
early or intermediate AMD was 59.5+5.7 years
(age range, 41.3–74.0 years) and the mean age of
those subjects with neovascular AMD was 61.1+
6.0 years (age range, 42.7–74.0 years). Thirty-six
per cent of the unaffected subjects, 18 per cent of
the AREDS category 2 and 3 AMD subjects and 46
per cent of the neovascular subjects were male.
Analysis of sunlight-associated
epidemiological factors
The analysis of epidemiological data was performed
on 133 extremely discordant sibling pairs, equalling
266 subjects. Twenty-six affected patients (19.5 per
cent) had skin cancer and 25 (18.8 per cent) of their
matched unaffected siblings also had skin cancer. Iris
colour in the affected patients was 42.9 per cent
blue (n ¼ 151), 24.8 per cent green (n ¼ 33) and
32.3 per cent brown (n ¼ 34). In the matched unaf-
fected patients iris colour was 41.6 per cent blue
(n ¼ 132), 25.0 per cent green (n ¼ 33) and 33.4
per cent brown (n ¼ 45). Of the affected siblings, 94
(70.6 per cent) reported taking multivitamin sup-
plements at least twice a week for at least six months
and 76 (57.1 per cent) of the unaffected patients
reported the same. Speciﬁc vitamin D supplemen-
tation was reported in 11 affected patients (8.3 per
cent) and 15 unaffected patients (11.3 per cent).
The average yearly UV index in the affected
patients was 5.24 W/m
2 (range, 4.42–7.49) and
5.43 W/m
2 (range, 4.37–7.49) in the unaffected
patients. Average yearly UV A in the affected patients
was 40.22 W/m
2 (range, 36.16–50.58) and 41.17
W/m
2 (range, 36.17–50.57). Average yearly UVB
in the affected patients was 0.99 W/m
2 (range,
0.84–1.41) and 1.03 W/m
2 (range, 0.84–1.41) in
the unaffected patients.
Single CLR regression showed that, of these
factors, UV , UV A and UVB irradiance were the
risk factors most signiﬁcantly associated with neo-
vascular AMD (Table 1) (p ¼ 0.0013 for all).
Analysis of self-reported sun exposure suggested a
protective effect for those who reported minimal
sun exposure 15 years in the past (p ¼ 0.04);
however, this did not remain signiﬁcant after cor-
rection for multiple testing. Skin cancer status, iris
colour, vitamin D supplementation and various
exposures of sunlight were not associated with neo-
vascular AMD risk in CLR analysis.
The backward selection model using previously
reported SNPs (12 in CFH and six in ARMS2/
HTRA1), smoking history and yearly UV irradi-
ance showed that the model most predictive of
neovascular AMD included smoking greater than
ten pack-years, CFH rs572515, HTRA1
rs1049331, and total UV index, UV A irradiance or
UVB irradiance (data not shown). Each UV irradi-
ance measure was shown to be signiﬁcant in the
multiple model (p ¼ 0.01 for all). Most signiﬁ-
cantly, for every one-unit increase in UV index
between 4.73 and 7.49, AMD risk was reduced
66.6-fold after controlling for smoking, CFH
rs572515 and HTRA1 rs1049331 (Table 2).
Analysis of serum levels of vitamin D
Serum 25(OH)D levels were measured for 100
patients comprising 50 extremely discordant sibling
pairs. Of the 50 unaffected siblings, 30 took multi-
vitamins, ﬁve took both multivitamins and vitamin
D supplements and one took vitamin D sup-
plements alone. The mean+SD serum 25(OH)D
levels in affected patients was 24.7+10.5 ng/ml
(concentration range, 5.1–49.6 ng/ml) and in
unaffected patients was 27.5+10.7 ng/ml (con-
centration range, 8.9–67.3 ng/ml). Serum 25(OH)D
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ing affected and unaffected siblings (p ¼ 0.22)
(Figure 1), or when controlling for the month in
which serum was collected.
RPE–choroid expression analysis
Of the vitamin D pathway-associated genes exam-
ined in a whole transcriptome analysis of ocular
tissues derived from 66 human donors, no
Table 1. Single factor analysis of epidemiological factors using conditional logistic regression
Distribution of continuous
variables (if applicable)
Risk factor Odds ratio (95%
confidence
interval)
p-Value Average Min Max
Vitamin D supplements for  6
months
0.862 (0.505–1.472) 0.5866
Multivitamin supplements for  6
months
0.667 (0.237–1.873) 0.4417
Serum 25(OH)D level (ng/ml) 0.973 (0.934–1.013) 0.1859 26.10 5.10 67.30
Blue eyes 1.064 (0.654–1.731) 0.8039
Green eyes 1.000 (0.573–1.744) 1.0000
Brown eyes 0.966 (0.579–1.613) 0.8960
Skin cancer 1.050 (0.570–1.933) 0.8762
Sun exposure now 1
† 1.071 (0.517–2.220) 0.8528
Sun exposure now 2
† 1.350 (0.757–2.407) 0.3090
Sun exposure now 3
† 0.929 (0.545–1.584) 0.7856
Sun exposure now 4
† 0.750 (0.407–1.382) 0.3562
Sun exposure now 1 or 2
† 1.381 (0.788–2.421) 0.2600
Sun exposure 15 years ago 1
† 0.955 (0.525–1.736) 0.8788
Sun exposure 15 years ago 2
† 1.333 (0.831–2.141) 0.2336
Sun exposure 15 years ago 3
† 1.045 (0.583–1.876) 0.8815
Sun exposure 15 years ago 4
† 0.375 (0.147–0.958) 0.0405
Sun exposure 15 years ago 1 or 2
† 1.409 (0.816–2.433) 0.2186
Year UV index (TUV)
‡ 0.115 (0.031–0.432) 0.0013 5.33 4.37 7.49
Year UV-A (TUV)
‡ 0.619 (0.463–0.829) 0.0013 40.69 36.16 50.58
Year UV-B (TUV)
‡ 0.009 (0.008–0.010) 0.0013 1.01 0.84 1.41
Year UV index (EPA)
§ 0.104 (0.020–0.541) 0.0071 4.13 1.00 10.00
Abbreviations: EPA, Environmental Protection Agency; Min, minimum; Max, maximum; 25(OH)D, 25-hydroxyvitamin D.
†Self-reported sun exposure 1: spends most of the day outside; self-reported sun exposure 2: spends most of free time outside; self-reported sun exposure 3: occasionally
spends a day in the sun; self-reported sun exposure 4: almost never outside.
‡As calculated using data from the TUV calculator (http://cprm.acd.ucar.edu/Models/TUV/Interactive_TUV/).
§As calculated using data from the US EPA SunWise Program (http://www.epa.gov/sunwise1/doc/uvimonth.html.
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disease status was observed; however, differences in
expression levels between the macular and extrama-
cular regions were observed. Expression of both
VDR and CYP27A1 was detected in the RPE–
choroid; CYP27A1 and CYP27B1 were detected
in the retina. CYP27A1 was expressed at low to
moderate levels, with signiﬁcant differences
detected between the extramacula and macula
regions (Figure 2A). Similar differences in the
extramacula:macula expression ratio of CYP27A1
were observed in both non-AMD (1.5-fold, p ¼
0.00012; one-tailed Mann–Whitney U test) and
AMD (1.7-fold, p ¼ 5   10
28) RPE–choroids.
Similar macula:extramacula expression differences
were observed for CYP27A1 (Figure 2C) and
CYP27B1 (Figure 2D) in the retina. VDR
expression in many RPE–choroid tissues was at or
below the level of detection, but was observed at
signiﬁcantly higher levels in several donors, conco-
mitant with an increased expression of genes
involved in local inﬂammatory responses (M.J.
Radeke, D.H. Anderson and L.V . Johnson, personal
communications). There was a trend of slightly
higher VDR expression in the macular region of
both normal and diseased RPE–choroids (1.3- and
1.5-fold, respectively) which rose to a level of sig-
niﬁcance (p ¼ 0.02) in the diseased RPE–choroid
(Figure 2B), but not the retina (data not shown).
Table 2. Multiple conditional logistic regression for UV irradiance
Risk factor Odds ratio (95% CI) p-Value
Year UV index 0.015 (0.001–0.433) 0.0143
Smoking   10 pack-years 3.581 (1.590–8.063) 0.0021
CFH rs572515 (additive model) 7.971 (2.960–21.459) 3.99E-05
HTRA1 rs1049331 (additive model) 9.829 (3.589–26.920) 8.77E-06
Risk factor Odds ratio (95% CI) p-Value
Year UV-A 0.368 (0.163–0.828) 0.0157
Smoking   10 pack-years 3.705 (1.631–8.418) 0.0018
CFH rs572515 (additive model) 8.403 (3.057–23.098) 3.69E-05
HTRA1 rs1049331 (additive model) 9.969 (3.618–27.467) 8.72E-06
Risk factor Odds ratio (95% CI) p-Value
Year UV-B 0.009 (0.000–0.011) 0.0153
Smoking   10 pack-years 3.606 (1.597–8.141) 0.0020
CFH rs572515 (additive model) 8.084 (2.985–21.895) 3.93E-05
HTRA1 rs1049331 (additive model) 9.869 (3.598–27.073) 8.73E-06
Abbreviation: CI, conﬁdence interval.
Figure 1. Analysis of serum levels of vitamin D in extremely
discordant sibpairs.
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Both cell lines were derived from a human retino-
blastoma; however, they were isolated and deemed
continuous at two separate institutions. As both cell
lines were derived from a retinoblastoma, and with
previous studies implicating vitamin D3 as a poten-
tial therapeutic agent for this cancer,
58 a subset of
genes involved in the vitamin D3 pathway were
selected for testing via qRT-PCR. Vitamin D treat-
ment of retinoblastoma cells did not result in sig-
niﬁcant changes in mRNA expression of any of the
genes investigated. The genes tested by qRT-PCR
were CYP24A1 and the calreticulin gene (CALR).
For these two genes, vitamin D3 treatment resulted
in gene expression changes of varying degrees in
both cell lines. A general increasing trend was
noted for CYP24A1, with peak expression
occurring at the 48-hour time point in
Weri-RB1-RB1-RB1 cells. By contrast, the Y79
cells exhibited a similar increasing trend, with peak
expression at six hours, but then followed by a
drastic decrease which remained until the ﬁnal time
point at 48 hours. CALR exhibited a pattern of an
initial increase in expression, followed by a sub-
sequent decrease and then a gradual increase over
the subsequent time points. In Weri-RB1 cells, this
was accompanied by peak expression at the ﬁnal
time point, while in Y79 cells the subsequent
decrease occurred later, with no subsequent
increase being noted owing to the decrease in
expression occurring at the ﬁnal time point at 48
hours. It would have been interesting to see if
expression began to increase at later time points, as
it did in Weri cells (see Figure 3).
Figure 2. RPE–choroid expression analysis.
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CYP24A1 SNPs in the extremely discordant
sibling pair cohort: Discovery cohort
No signiﬁcant deviations from Hardy–Weinberg
equilibrium were observed for any of the variants
studied in VDR, CYP27A1, CYP27B1 and
CYP24A1 in unaffected siblings. Of the four genes
tested, variation within both VDR and CYP24A1
were found to be signiﬁcantly associated with neo-
vascular AMD. In VDR, rs2189480 (intron 4) was
found to be signiﬁcantly associated with risk of
neovascular AMD by FBAT (p ¼ 0.02) (Table 3).
In FBAT, the minor alleles of CYP24A1 rs6127118
(intron 7) and rs2762934 (exon 12) were found to
be associated with risk of neovascular AMD (p ¼
0.03 and p ¼ 0.01). Two haplotype blocks were
shown to be signiﬁcantly associated with neovascu-
lar AMD risk in FBAT (Figure 4). In block 4,
comprising rs6068816 (exon 6) and rs6127118
(intron 7), haplotype h1 (GC) was modestly signiﬁ-
cant (p , 0.03) and haplotype h2 (GT) was signiﬁ-
cant under an additive model (p ¼ 0.002). In block
5, comprising rs1570669 (intron 9), rs927650
(intron 11) and rs2762934 (exon 12), haplotype h3
(TGT) was signiﬁcantly associated (p ¼ 0.01). Due
to the fact that these haplotypes were more signiﬁ-
cantly associated with AMD than any single SNP
alone, and that there is more power to detect an
association through haplotypes,
59 we used these
regions to drill down in the replication and vali-
dation cohorts.
Sequencing of area surrounding signiﬁcant
variation
Based on the initial ﬁndings of signiﬁcant variation
within VDR and CYP24A1, a combination of
direct sequencing and NextGen sequencing was
performed on 95 neovascular patient samples in
order to capture variation beyond the signiﬁcantly
associated tagging SNPs to include exons and sur-
rounding exon/intron borders. Speciﬁcally, exons 4
and 5 of VDR and exons 4–12 of CYP24A1 were
assayed for variation. No further variation was
found within VDR, but the following 22 SNPs
were found in the regions investigated in
CYP24A1: rs2296241, rs4809960, rs4809959,
rs2181874, rs6068816, rs6022993, rs6091828,
rs6127119, rs6127118, rs2296239, rs2274130,
rs1570670, rs1977297, rs1570669, rs927650,
rs2762934, rs4809957, rs6022987, rs11907350,
rs10623012, rs4811494 and rs2762933 (see
Table S2). Additionally, novel variations were found
within CYP24A1 intron 7 at c.990 þ 189 (chromo-
some 20: 52,779,066; G . A) and c.990 þ 222–223
(chromosome 20: 52,779,033; an insertion of 99 bp of
the sequence GCGCACAGCATCTATACCACGGT
GCCTCAGCGCACGGCCTCATACTAGACACCA
CGGTGCCTCCGCGCACGGCCTCATACCAG
ACGCCACGGTGCCTCC). Both variants were
conﬁrmed by sequencing in the reverse direction.
Further direct sequencing showed the 99 bp insert
to be a repeated sequence. Patients were found to be
both homozygous and heterozygous for this repeat.
Interestingly, an alternative heterozygote was found
that consisted of one 99 bp repeat and a second,
smaller insert. This second insert had the same
sequence as that described for rs3831062 but at a
different location than that initially described
(chromosome 20: 52,779,033; an insertion of 35 bp
Figure 3. Vitamin D treatment.
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Marker Allele Frequency Informative
families
Z
score
p-Value
CYP27A1
rs7594289 G 0.428 51 20.808 0.4189
rs7566656 A 0.485 60 1.179 0.2383
CYP27B1
rs8176345 A 0.030 ,2 0.000 1.0000
rs4646536 C 0.324 ,2 0.000 1.0000
VDR
rs4516035 G 0.443 47 1.116 0.2643
rs7299460 A 0.262 36 1.333 0.1824
rs10783219 A 0.361 42 20.630 0.5287
rs7136534 A 0.238 35 1.622 0.1048
rs11574026 T 0.120 23 0.626 0.5316
rs11574027 T 0.017 2 1.414 0.1573
rs4237855 T 0.490 47 20.329 0.7419
rs4328262 A 0.568 49 0.956 0.3390
rs11168287 C 0.485 56 20.570 0.5688
rs4760648 A 0.447 52 20.640 0.5221
rs2853564 C 0.395 46 0.000 1.0000
rs2238136 A 0.283 43 21.000 0.3173
rs2254210 T 0.369 54 0.843 0.3994
rs10735810 T 0.374 48 0.739 0.4602
rs10875693 A 0.679 46 0.000 1.0000
rs2239186 C 0.248 44 20.137 0.8907
rs3782905 G 0.282 34 20.152 0.8788
rs3819545 C 0.427 54 0.226 0.8208
rs2189480 C 0.593 45 21.807 0.0707
rs12721370 T 0.112 15 1.414 0.1573
rs12717991 G 0.564 51 0.000 1.0000
rs2239179 G 0.349 47 20.911 0.3621
rs2283342 C 0.205 38 20.302 0.7630
Continued
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Marker Allele Frequency Informative
families
Z
score
p-Value
rs2107301 T 0.340 46 0.405 0.6858
rs2239182 G 0.420 46 0.788 0.4308
rs11574077 G 0.028 10 20.632 0.5271
rs11168267 T 0.116 17 0.728 0.4669
rs7975128 T 0.333 45 0.132 0.8946
rs1544410 A 0.337 46 20.640 0.5221
rs7975232 T 0.494 52 0.239 0.8111
rs731236 C 0.320 45 20.775 0.4386
rs3847987 T 0.150 28 1.029 0.3035
CYP24A1
rs2248359 A 0.425 49 20.611 0.5413
rs6022999 C 0.250 42 21.089 0.2763
rs2585428 A 0.441 56 20.342 0.7324
rs2245153 G 0.201 48 1.089 0.2763
rs4809960 G 0.229 51 1.192 0.2332
rs4809959 C 0.500 46 0.122 0.9028
rs2181874 T 0.247 45 21.633 0.1025
rs3787557 G 0.144 40 1.265 0.2059
rs3787555 T 0.263 42 1.260 0.2076
rs3787554 T 0.065 20 0.209 0.8348
rs4809958 C 0.128 25 1.134 0.2568
rs2762939 G 0.275 36 20.816 0.4142
rs6068816 A 0.079 22 0.000 1.0000
rs6127118 T 0.157 22 2.132 0.0330
rs2209314 G 0.256 43 21.387 0.1655
rs1570669 C 0.335 45 0.630 0.5287
rs927650 G 0.511 44 20.391 0.6961
rs2762934 T 0.156 29 22.535 0.0112
rs6097807 C 0.241 50 21.131 0.2579
rs6068810 A 0.059 17 0.728 0.4669
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GTATGAGGCCGTGCGC). Direct sequencing was
performed for all subsequent variation of this
sequence. This 99 bp insertion was not associated
with AMD in either the sibling cohort or the Greek
cohort.
Analysis of VDR and CYP24A1 SNPs in the
replication cohorts
Based on the results of direct sequencing, 24 SNPs/
structural variants were genotyped in the extended
sibling cohort consisting of 657 individuals/481
sibling pairs and the unrelated case–control cohort
from central Greece by a combination of Sequenom,
Taqman and direct sequencing. Based on the prelimi-
nary ﬁndings of association in the discovery and
expanded sibling cohorts, the following 12 SNPs were
genotyped in the NHS/HPFS cohort: VDR
rs2189480, CYP24A1 rs2181874, rs6127118, c.990
þ 222–223ins99, rs2296239, rs2274130, rs1570670,
rs1570669, rs927650, rs2762934, rs4809957 and
rs11907350.
Haplotype analysis of CYP24A1
Haploview, using haplotype blocks deﬁned by the
Gabriel rule,
54 demonstrated that in the extended
sibling cohort there were four haplotype blocks span-
ning the more than 16,000 base pairs covered by gen-
otyping (Figure 5). Of these haplotype blocks, none
was shown to be signiﬁcantly associated with any
subtype of AMD risk by either FBAT analysis or
UNPHASED analysis (data not shown). Similar
results were found for the Greek cohort and the
NHS/HPFS in UNPHASED (data not shown).
Those CYP24A1 SNPs that were shown to have
a p-value   0.12 in the analysis of individual SNPs
using UNPHASED were analysed in a backward
selection fashion and, additionally, by using a
sliding window approach for haplotype association
using the same program. In each of the four
cohorts, no method identiﬁed signiﬁcant haplo-
types (data not shown).
Meta-analysis of VDR and CYP24A1
Comprehensive meta-analysis v2 was used to
analyse the variation which had been genotyped in
all populations. VDR rs2189480 was not signiﬁ-
cantly associated with AMD. Several SNPs within
CYP24A1 were shown to be signiﬁcant by
meta-analysis. When comparing all AMD with
unaffected patients, rs1570669, rs1570670,
rs2274130, rs2296239 and rs4809957 were all sig-
niﬁcantly associated with AMD (p ¼ 0.0005, p ¼
0.02, p ¼ 0.008, p ¼ 0.02 and p ¼ 0.03, respect-
ively). For each of these SNPs, the overall p-value
obtained by meta-analysis was more signiﬁcant than
that for each of the cohorts analysed where, in
some cases, these SNPs were not individually sig-
niﬁcant (Table 4). Cochran’s Q, the measure of
heterogeneity, was signiﬁcant for SNP rs927650
Figure 4. Signiﬁcant CYP24A1 haplotypes in discovery cohort.
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Expanded sibpair cohort Greeks NHS/HPFS Meta-analysis
SNP Gene Allele Odds ratio
(95% CI)
p-Value Odds ratio
(95% CI)
p-Value Odds ratio
(95% CI)
p-Value Odds ratio
(95% CI)
p-Value
rs2189480 VDR A 1.801 (1.069–3.035) 0.0270 1.199 (0.846–1.700) 0.3080 0.903 (0.766–1.064) 0.2213 0.997 (0.865–1.151) 0.9710
rs2296241 CYP24A1 C 1.345 (0.829–2.182) 0.2294 1.185 (0.842–1.668) 0.3306 1.036 (0.814–1.319) 0.7711
rs4809960 CYP24A1 G 0.983 (0.567–1.703) 0.9515 1.027 (0.690–1.527) 0.8967 1.116 (0.843–1.477) 0.4425
rs4809959 CYP24A1 T 1.238 (0.770–1.989) 0.3781 1.058 (0.761–1.470) 0.7369 1.124 (0.885–1.427) 0.3391
rs2181874 CYP24A1 T 0.871 (0.501–1.515) 0.6242 0.687 (0.481–0.983) 0.0400 0.989 (0.812–1.204) 0.9116 0.894 (0.763–1.046) 0.1629
rs6068816 CYP24A1 A 2.081 (0.945–4.586) 0.0690 1.141 (0.695–1.875) 0.6012 1.243 (0.851–1.817) 0.2600
rs6091828 CYP24A1 A 1.338 (0.281–6.382) 0.7148 0.536 (0.206–1.393) 0.2006 0.745 (0.356–1.560) 0.4352
rs6127119 CYP24A1 A 1.284 (0.724–2.274) 0.3924 1.245 (0.831–1.865) 0.2881 1.257 (0.937–1.688) 0.1275
c.990 þ 189
G . A
CYP24A1 A 0.887 (0.138–5.700) 0.8993 1.699 (0.323–8.925) 0.5312 1.123 (0.347–3.630) 0.8464
rs6127118 CYP24A1 T 1.297 (0.725–2.319) 0.3816 1.274 (0.845–1.921) 0.2471 1.050 (0.864–1.276) 0.6230 1.111 (0.946–1.305) 0.1995
c.990 þ 222–
223 ins99
CYP24A1 ins 1.341 (0.744–2.417) 0.3288 1.297 (0.867–1.939) 0.2055 1.086 (0.874–1.350) 0.4564 1.145 (0.963–1.363) 0.1258
rs2296239 CYP24A1 A 1.457 (0.819–2.590) 0.2000 1.529 (0.976–2.396) 0.0638 1.205 (0.993–1.463) 0.0584 1.217 (1.035–1.430) 0.0174
rs2274130 CYP24A1 C 1.751 (0.975–3.147) 0.0610 1.512 (0.970–2.358) 0.0679 1.255 (1.029–1.529) 0.0247 1.248 (1.059–1.47) 0.0082
rs1570670 CYP24A1 C 1.790 (0.981–3.267) 0.0579 1.512 (0.970–2.358) 0.0679 1.195 (0.984–1.452) 0.0725 1.220 (1.037–1.436) 0.0165
rs1977297 CYP24A1 A 0.725 (0.293–1.791) 0.4856 1.142 (0.621–2.101) 0.6693 1.009 (0.643–1.582) 0.9694
rs1570669 CYP24A1 C 1.153 (0.690–1.927) 0.5875 1.287 (0.894–1.852) 0.1753 1.309 (1.104–1.551) 0.0019 1.285 (1.116–1.478) 0.0005
rs927650 CYP24A1 A 0.914 (0.596–1.402) 0.6804 1.468 (1.048–2.056) 0.0257 0.853 (0.728–0.999) 0.0487 0.969 (0.852–1.102) 0.6316
rs2762934 CYP24A1 T 0.743 (0.367–1.502) 0.4082 1.067 (0.704–1.619) 0.7595 0.930 (0.754–1.148) 0.5016 0.949 (0.798–1.130) 0.5574
rs4809957 CYP24A1 C 1.475 (0.822–2.644) 0.1925 1.462 (0.943–2.268) 0.0896 1.191 (0.981–1.445) 0.0772 1.196 (1.017–1.405) 0.0300
rs6022987 CYP24A1 G 0.755 (0.427–1.336) 0.3347 1.169 (0.804–1.699) 0.4136 1.109 (0.845–1.456) 0.4567
rs11907350 CYP24A1 T 0.363 (0.066–2.000) 0.2445 1.296 (0.438–3.836) 0.6397 1.246 (0.829–1.872) 0.2896 1.111 (0.772–1.598) 0.5711
Abbreviation: CI, conﬁdence interval; SNP, single nucleotide polymorphism.
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1(p ¼ 0.02). This was the SNP that the minor allele
was deﬁned as (A) and the Sibling cohort and the
NHS/HPFUS, but was deﬁned as (G) in the
Greeks. Overall, the test for heterogeneity was not
statistically signiﬁcant (p . 0.1).
Bioinformatic analysis of potential function
of variants
Of the SNPs found to be signiﬁcantly associated with
AMD, three SNPs were well conserved across species:
rs2296239, rs2274130 and rs1570670, spanning from
exon 8 to intron 9 of CYP24A1. Transcription
Element Search System (TESS) analysis showed that,
of our ﬁve signiﬁcant SNPs, three SNPs changed or
created transcription factor binding sites with the
presence of the minor allele. Speciﬁcally, the minor
allele of rs2274130 eliminated the binding site of B
factor T00286 factor i T00557 NF-E2; rs1570670
changed the binding site from Gata-1 to GR; and
the minor allele of rs1570669 changed the binding
site from NF-BA1 to STE12. Using the publicly
available eQTL database mRNA by SNP Browser v
1.0.1,
56,57 we investigated the association of the
CYP24A1 SNPs that were signiﬁcant alone or as
part of a haplotype with eQTLs. Of our six
SNPs, rs2181874 and rs1570669 were associated
with the genes TSC22 domain family, member 1
(TSC22D1), unc-51-like kinase 2 (ULK2) and ring
ﬁnger protein 213 (RNF213), respectively. These
results suggest that further experimental analysis of
these datawould be worthwhile.
In order to identify causal variation, the creation of
putative splice sites by genetic variants was analysed
b yi n p u t t i n gs e q u e n c ei n t ot h ea l t e r n a t i v es p l i c es i t e
predictor (http://www.es.embnet.org/~mwang/assp.
html) (using the default parameters). Splice site analy-
sis of the minor allele (G) of rs927650—the SNP
most signiﬁcantly associated with an increased risk of
AMD in the Greek cohort—predicted the creation
of an alternative isoform/cryptic donor at the bp
immediately preceding this SNP (chromosome 20:
52772742) within intron 11 of the longest CYP24A1
transcript (CYP24A1-003) with a score of 10.967.
Further studies should be conducted to test this pre-
diction in a biological setting.
Pathway analyses
IPA analyses indicated that ﬁve genes (RXRA, VDR,
PTH, CYP24 and CYP24A1) involved in the regu-
lation of vitamin D metabolism, are connected
by direct and indirect relationships to one
AMD-associated gene (HTRA1) for which the
pathway is unknown.
10,38,52,60–62 Additionally, some
of these pathway genes directly or indirectly interact
with genes involved in angiogenesis (the CALR,
catenin [cadherin-associated protein] beta 1
(CTNNB1), bone morphogenetic protein 4 (BMP4)
and interleukin 6 [IL6] genes), one of the hallmarks of
neovascular AMD.
As the pathway map shows (Figure 6), some of
the genes are implicated in both AMD and vitamin
D pathways (VDR and CYP24A1), or both angio-
genesis and AMD (BMP4). When the pathways
linking the genes/proteins described above are
grown to incorporate other related molecules, the
retinoid X receptor-a gene (RXRA), encoding a
ligand-dependent nuclear receptor which binds
directly to VDR, is identiﬁed as a potentially rel-
evant gene in the pathogenesis of AMD, given its
role in the inﬂammatory response. Clearly, the
genes illustrated in our pathway map are involved
in multiple processes. Although it is a hypothetical
pathway, the map may help to explain the protec-
tive anti-inﬂammatory and anti-angiogenic role of
vitamin D in the likelihood of developing AMD.
Analysis of interactions between gene variants
and environmental factors
For gene–gene interactions, all CYP24A1 SNPs
were tested for interaction with well-established
risk genotypes in ARMS2/HTRA1, CFH and
RORA for which we had previous genotyping data
and, furthermore, for interaction with VDR
rs2189480. Analysis of all AMD subtypes compared
with unaffected individuals showed several
CYP24A1 SNPs and VDR rs2189480 to interact
modestly, but these associations did not remain sig-
niﬁcant after adjusting for multiple comparisons.
The pooled case-only analysis showed no signiﬁ-
cant interactions between CYP24A1 SNPs and
VDR rs2189480.
Systems biology-based analysis implicates a role for vitamin D metabolism in AMD PRIMARY RESEARCH
# HENRY STEWART PUBLICATIONS 1479–7364. HUMAN GENOMICS. VOL 5. NO 6. 538–568 OCTOBER 2011 557Interaction between both CYP24A1 and VDR
variants and sunlight exposure was also tested using
CLR in SAS. No signiﬁcant interaction was found
between UV irradiation and any of the variants
tested (data not shown).
Discussion
Many pathways and processes involved in the pro-
gression of systemic disorders such as cancer, cardi-
ovascular disease and autoimmune diseases are also
Figure 6. IPA pathway analysis of vitamin D metabolism. Graphical representation of the relationships between genes/proteins
(represented as nodes). The biological relationship between two nodes is represented as a line (segmented to illustrate indirect
relationships and continuous to illustrate direct relationships). All lines are supported by at least one reference from the literature or
from canonical information stored in the Ingenuity Pathways Knowledge Base. Nodes are displayed using various shapes to illustrate the
functional class of the gene product.
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that valuable insights into the pathophysiology of
AMD may be gained by studying pathways common
to AMD and other well-characterised diseases that
may overlap in pathogenesis. In fact, cross-talk
between disease ﬁelds has already proven beneﬁcial
for the treatment of AMD: anti-vascular endothelial
growth factor (anti-VEGF) antibodies initially
developed for the treatment of cancer are currently
the most effective treatment for neovascular AMD.
3
The important role of vitamin D in diseases of
complex aetiology, its anti-angiogenic properties
and an association between vitamin D serum levels
and early AMD led us initially to explore the
association between vitamin D and neovascular
AMD by examining vitamin D-associated epide-
miological factors and genetic variants of vitamin
D metabolism genes in an extremely discordant
sibling pair cohort. Here, we showed a protective
effect of UVexposure on the development of neo-
vascular AMD. Further, we identiﬁed several
CYP24A1 SNPs signiﬁcantly associated with all
subtypes of AMD in four diverse cohorts, both
retrospectively and prospectively. Moreover, these
signiﬁcant associations were demonstrated in a
meta-analysis of the four cohorts. To the best of
our knowledge, this was the ﬁrst study to demon-
strate a protective effective of UV exposure on the
development of AMD and a genetic link between
vitamin D metabolism and AMD.
The role of sunlight in AMD pathophysiology
remains controversial. Human exposure to natural
sunlight may be both beneﬁcial and detrimental.
One beneﬁt of cutaneous sunlight exposure is the
production of vitamin D. Studies have also shown
that vitamin D produced as a result of sunlight
exposure reduces the risk of autoimmune diseases
such as multiple sclerosis (MS) and inﬂammatory
bowel disease (IBD).
63 By contrast, natural sunlight
(ie UV exposure) has long been known to have
harmful effects on the human body, including per-
manent DNA damage. For example, studies have
linked sunlight exposure to skin cancer, for both
melanomas
64,65 and carcinomas.
66 In dermatologi-
cal malignancies, the most detrimental factor is
UVB, but UV A may also play a role.
To distinguish between the effects of general
sunlight exposure and speciﬁcally UV exposure,
sunlight exposure was self-assessed by patients and
UV exposure was quantiﬁed separately by examin-
ing UV radiation, as measured in irradiance of
UVB (290 nm to 320 nm), UV A (320 nm to
400 nm) and UV index. In addition, we examined
vitamin supplementation, as well as sun-related
variables including iris colour, self-reported sun
exposure and skin cancer history. We also measured
25(OH)D in sera as a biomarker for vitamin D
levels. To the best of the authors’ knowledge, this
was the ﬁrst examination of sunlight exposure in
the context of established AMD risk genotypes and
smoking.
Quantiﬁcation of sunlight exposure is difﬁcult, as
it is an ongoing life-long process.
67–79 One of the
ﬁrst studies of ocular exposure to UV based on
interview data and ﬁeld measurements in
Chesapeake Bay watermen demonstrated no associ-
ation between UV exposure and AMD.
79 Further
analysis of this same dataset showed that there was
in fact an association between AMD and ocular
exposure, but to blue light speciﬁcally.
76,78
Alternatively, various studies have tested the associ-
ation of sunlight exposure and AMD by measuring
various sun-related variables. For example, Khan
et al. investigated the role of variables such as iris
colour, place of residence and hair colour but
found no association between AMD and these sun
related factors.
80 Cruickshanks et al. measured life-
time number of sunburns, use of hats and sunglasses
and number of hours spent outdoors, and showed
an association between leisure time spent outdoors
and risk of early AMD.
69 Our study demonstrated a
protective effect of moderate levels of UV radiation
exposure and AMD, independent of smoking
history and CFH and HTRA1 genotype. While
experimental studies have shown that UV light has
damaging effects on the retina—primarily via oxi-
dative damage and formation of reactive oxygen
species
81—previous epidemiological studies have
shown inconsistent results regarding an association
between UV light and risk of AMD.
67–79 UV light
is part of the sunlight spectrum, but only UV A
(320–400 nm) and UVB (280–320 nm) reach the
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sidered harmful because it induces DNA damage
and causes oxidative damage to RPE cells.
82–84
Furthermore, UV light has been shown to have
pro-angiogenic properties. UV A-irradiated RPE
cells have been shown to have increased levels of
prostaglandin–endoperoxide synthase 2 (also
known as cyclooxygenase-2 [COX2]),
85 which is
implicated in choroidal neovascularisation.
86
UVB-induced tumours express elevated levels of
factors associated with angiogenesis, including
VEGF , matrix metallopeptidase 2 (MMP2) and
matrix metallopeptidase 3 (MMP3).
87
Emerging evidence shows that solar radiation may
have beneﬁcial effects, however. Epidemiological
studies have demonstrated that sunlight reduces the
incidence and mortality of various cancers, including
non-Hodgkin’s lymphoma and melanoma.
88,89 UV
light is known to suppress the immune response
90
and growing evidence points to the role of inﬂam-
mation in AMD pathogenesis. Since aberrant
inﬂammation is believed to be a contributing factor
to AMD, the immunosuppressive effects of UV
radiation may provide some protective effect.
We speciﬁcally examined the role of UV light
and AMD in this study, although previous studies
have mainly looked at ambient sunlight exposure.
Previous studies have been inconsistent about the
role of sunlight exposure and AMD.
67–79,91,92
Some studies suggested a positive associ-
ation,
69,76,91,92 while others found no corre-
lation.
71,78,93 To our knowledge, our study was the
ﬁrst to show a protective inﬂuence of UV light on
neovascular AMD. Our ﬁnding may contrast with
previous studies as a result of using a larger number
of neovascular cases (n ¼ 133) than that used in
most previous studies. Furthermore, previous
studies measured ambient solar radiation, which
includes light of various wavelengths (UV , infrared,
visible), while our study distinguished the contri-
bution of UV irradiance.
Although our gene expression studies on vitamin
D metabolism genes in human donor eyes found
no signiﬁcant association as a function of age or
disease status, differences in expression levels
between the macular and extramacular regions were
observed. Speciﬁcally, the expression of both VDR
and CYP27A1 was detected in the RPE–choroid,
and CYP27A1 and CYP27B1 were detected in the
retina, thus suggesting that the vitamin D metabolic
genes VDR and CYP27B1 may function differently
between the maculae and extramaculae, whether
diseased or non-diseased. Also, AMD may not be a
localised disease but rather may manifest systemi-
cally, and this may explain why CYP24A1 was not
detected in human retinal tissue regardless of
disease status. The gene expression changes that we
observed in retinal cell lines suggested that
CYP24A1 activity may alter over time and this
would support its role in a late-onset disease such
as AMD.
There were several limitations to this study. First,
there was the possibility of recall bias. There was no
deﬁnitive method to conﬁrm an individual’s recall
of personal sun exposure and thus data could have
been prone to misclassiﬁcation. We attempted to
minimise this bias by using a quantitative measure-
ment of UV exposure based on the geographical
location where the participants had resided for the
majority of their lifetime; however, assessment of
UV radiation based on residential history represents
potential rather than actual exposure and could be
subject to error. Secondly, although the subjects
were questioned about the amount of time they
spent outdoors, no information was gathered about
their use of protection against sunlight, such as hats
and sunglasses, which shield against UV light.
Further, the subjects’ sera were collected at various
times throughout the year, and thus serum levels of
vitamin D measured in this study may not accu-
rately have represented the true range among the
patient population, since vitamin D levels are inﬂu-
enced by sunlight exposure, diet and age.
Although a previous study by Parekh et al.
showed an inverse relationship between vitamin D
levels and early AMD but not late AMD,
34 this
study was limited by a small number of patients
with an advanced form of AMD (n ¼ 10). A more
recent study by Millen et al. was able to show a stat-
istically signiﬁcant association between serum
25(OH)D concentrations and early AMD in
women younger than 75 years; speciﬁcally, that
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tective.
94 In our study, we further investigated the
association of serum levels of 25(OH)D, the circu-
lating form of vitamin D, with neovascular AMD
by analysing the serum levels of 50 extremely dis-
cordant sibling pairs (n ¼ 100). Our results were
similar to those found by Millen and colleagues: a
trend towards higher levels of vitamin D in the
serum of unaffected patients compared with neo-
vascular patients, although the difference was not
statistically signiﬁcant. Since the ability to produce
vitamin D is diminished with advanced age
(ageing results in decreased amounts of cutaneous
7-dehydrocholesterol, and by 70 years of age
vitamin D3 synthesis is reduced by approximately
75 per cent
95), it is not unexpected that serum
vitamin D levels were low, given that the average
age of our unaffected patients was 75.4 years. This
could explain why the association was not signiﬁ-
cant. Additionally, since this was measured only
once, the serum values reﬂected the vitamin D pro-
duction/intake over a limited amount of time, thus
suggesting enhanced random measurement error.
In addition to epidemiological data, the associ-
ation of AMD with genetic variation in vitamin D
pathway genes was further suggested by existing
linkage data for genomic regions associated with
AMD. The vitamin D pathway genes assayed in this
study all lie within regions that have been associated
with AMD — speciﬁcally, 2q33
48 (CYP27A1),
12q13
36 (CYP27B1 and VDR), and 20q13
36
(CYP24A1).
The CYP24A1 SNPs signiﬁcantly associated
with neovascular AMD in the discovery cohort
(either individually [rs6127118 and rs2769234] or
as part of a haplotype [rs6068816, rs6127118,
rs1570699, rs92760 and rs2762934]) were concen-
trated in the area between exon 6 and exon 12.
This area was further examined and reﬁned by
direct sequencing and analysed in an extended
sibling cohort. After controlling for smoking
history, sex and age, we were able to show signiﬁ-
cant variation in CYP24A1 in all populations, both
separately and, more importantly, in a meta-analysis.
Variation within CYP24A1 was available in the
dbGAP dataset (http://www.ncbi.nlm.nih.gov/
projects/gap/) but, when tested for association with
AMD, no signiﬁcance was observed. This lack of
association could be explained by the small number
of subjects in the dbGAP dataset, as compared with
the current study (n ¼ 500 and 2,528, respectively).
Additionally, these data were based on a 100,000
SNP chip, and the CYP24A1 variation was
imputed with low imputation quality, which is
another limitation of the dbGAP dataset.
Moreover, pathway analysis showed that, in a
hypothetical pathway, CYP24A1 was directly
linked to another AMD-associated gene, HTRA1,
for which the exact pathway is unknown. In a
complex disease such as AMD, one would expect
the combination of multiple effects, including the
modest effect of CYP24A1, to contribute to
disease causality. Although there was no statistical
interaction seen between CYP24A1 and HTRA1,
there may have been binding between the two that
differed between those with and those without
AMD. Further molecular studies should be per-
formed to investigate this association.
An anti-angiogenic role for vitamin D has been
well documented in the cancer literature.
96–98
Therefore, a role for vitamin D may be protective
of AMD by its anti-angiogenic properties.
27 For
example, VEGF expression was downregulated after
tumour cells were treated with vitamin D.
25,26
Vitamin D may exert anti-inﬂammatory properties
by enhancing T suppressor cell activity and down-
regulating T helper cells, T cytotoxic cells and
natural killer cells.
28 At physiological concen-
trations, vitamin D has also been shown to protect
cell proteins and membranes from oxidative
damage.
30 In addition to playing a role in cancer,
the vitamin D pathway has been implicated in
several autoimmune diseases. Several studies have
found that low levels of vitamin D are associated
with increased autoimmunity.
A role for vitamin D in AMD is not only plaus-
ible in terms of the known biological roles of
vitamin D, but also because of the diminished
ability to produce vitamin D with advanced age.
99
The problem of vitamin D deﬁciency is not only
prevalent among the elderly: as of 2005, approxi-
mately 40 per cent of men and 50 per cent of
Systems biology-based analysis implicates a role for vitamin D metabolism in AMD PRIMARY RESEARCH
# HENRY STEWART PUBLICATIONS 1479–7364. HUMAN GENOMICS. VOL 5. NO 6. 538–568 OCTOBER 2011 561women aged over 18 from the USA were estimated
to have inadequate levels of 25(OH)D.
100
Conclusion
In summary, using multiple lines of evidence, this
study demonstrated an association between the
vitamin D pathway and AMD. Speciﬁcally, there is
a protective association between UV radiation and
neovascular AMD which is independent of
smoking and CFH and HTRA1 polymorphisms.
Additionally, we identiﬁed an association between
genetic variation in the major vitamin D catabolic
gene, CYP24A1, and risk for all forms of AMD
and, speciﬁcally, the neovascular form of AMD.
Further experiments are needed to elucidate the
role of vitamin D and UV light in the pathogenesis
of AMD. Ongoing large-scale trials of supplemental
vitamin D may provide a unique opportunity to
examine the effects of vitamin D on AMD in a
randomised trial setting. Such studies may have
important implications for the prevention and/or
treatment of neovascular AMD by the regulation of
modiﬁable lifestyle factors that inﬂuence levels of
vitamin D.
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Table S1. Subject characteristics
Population Mean age Range Standard deviation % Male
Massachusetts Eye and Ear Infirmary Extremely Discordant Sibling Pair Discovery Cohort (n 5 270 individuals from
135 families)
Neovascular subjects (n ¼ 135) 71.7 49.0–85.5 8.0 47%
Control subjects (n ¼ 135) 76.0 50.3–93.9 7.6 39%
Massachusetts Eye and Ear Infirmary Cohort Extended Sibling Pair Cohort (n ¼ 657 individuals from 284 families)
Population Mean age Range Standard deviation % Male
Neovascular subjects (n ¼ 353) 73.9 49.0–94.0 7.8 41%
Dry subjects (n ¼ 106) 77.6 58.2–100.6 7.2 35%
Control subjects (n ¼ 198) 75.4 50.3–94.3 8.3 44%
Central Greece cohort (n ¼ 344 individuals)
Population Mean age Range Standard deviation % Male
Neovascular subjects (n ¼ 139) 76.23 49.0–94.0 7.5 45%
Dry subjects (n ¼ 84) 74.52 52.0–91.0 7.8 44%
Control subjects (n ¼ 121) 73.53 48.0–88.0 7.3 51%
Prospective-based cohort derived from the Nurses’ Health Study/Health Professionals Study (n ¼ 1,527 individuals)
Population Mean age Range Standard deviation % Male
Neovascular subjects (n ¼ 164) 61.1 42.7–74.0 6.0 46%
Dry subjects (n ¼ 293) 59.5 41.3–74.0 5.7 18%
Control subjects (n ¼ 1070) 60.2 41.3–74.0 5.9 36%
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†
Gene SNP Exon/intron
‡ Position (bp)
CYP27A1 rs11677711* Intron 1 chr2: 219,669,375
rs7566656* Intron 1 chr2: 219,664,519
rs7594289* Intron 1 chr2: 219,652,286
rs933994* Intron 1 chr2: 219,650,616
CYP27B1 rs8176345* Exon 5 chr12: 58,158,558
rs4646536* Intron 6 chr12: 58,157,988
VDR rs4516035* Promoter chr12: 48,299,826
rs7299460* Intron 1 chr12: 48,296,268
rs10783219* Intron 1 chr12: 48,295,488
rs7136534* Intron 1 chr12: 48,294,626
rs3890733* Intron 2 chr12: 48,289,373
rs11574026* Intron 2 chr12: 48,288,246
rs11574027* Intron 2 chr12: 48,287,373
rs4237855* Intron 2 chr12: 48,287,203
rs4328262* Intron 2 chr12: 48,285,648
rs11168287* Intron 2 chr12: 48,285,414
rs4760648* Intron 2 chr12: 48,280,665
rs2853564* Intron 2 chr12: 48,278,487
rs2238136* Intron 2 chr12: 48,277,713
rs2254210* Intron 3 chr12: 48,273,714
rs2228570
§,* Exon 4 chr12: 48,272,895
rs10875693* Intron 4 chr12: 48,269,650
rs2239186* Intron 4 chr12: 48,269,410
rs3782905* Intron 4 chr12: 48,266,167
rs3819545* Intron 4 chr12: 48,265,006
rs2189480* Intron 4 chr12: 48,263,828
rs12721370* Intron 4 chr12: 48,262,073
rs12717991* Intron 4 chr12: 48,259,126
rs2239179* Intron 5 chr12: 48,257,766
rs2283342* Intron 5 chr12: 48,255,859
rs2107301* Intron 5 chr12: 48,255,570
Continued
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Gene SNP Exon/intron
‡ Position (bp)
rs2239182* Intron 5 chr12: 48,255,411
rs11574077* Intron 5 chr12: 48,252,927
rs11168267* Intron 5 chr12: 48,251,542
rs7975128* Intron 8 chr12: 48,245,828
rs1544410* Intron 10 chr12: 48,239,835
rs7975232* Intron 10 chr12: 48,238,837
rs731236* Exon 11 chr12: 48,238,757
rs3847987* Exon 11 chr12: 48,238,068
CYP24A1 rs2248359* Promoter chr20: 52791518
rs6022999* Intron 3 chr20: 52788013
rs2585428* Intron 3 chr20: 52786897
rs2245153* Intron 3 chr20: 52786406
rs2296241 Exon 4 chr20: 52786219
rs4809960* Intron 4 chr20: 52786073
rs4809959* Intron 4 chr20: 52785859
rs2181874* Intron 4 chr20: 52784478
rs3787557* Intron 4 chr20: 52783135
rs3787555* Intron 4 chr20: 52782691
rs3787554* Intron 4 chr20: 52782680
rs4809958* Intron 4 chr20: 52782438
rs2762939* Intron 5 chr20: 52781251
rs6068816* Exon 6 chr20: 52781091
rs6022993 Intron 7 chr20: 52779247
rs6091828 Intron 7 chr20: 52779210
rs6127119 Intron 7 chr20: 52779082
c.990 þ 189 G . A Intron 7 chr20: 52779066
rs6127118* Intron 7 chr20: 52779052
c.990 þ 222_223ins99 Intron 7 chr20: 52779033
rs2209314* Intron 7 chr20: 52778961
rs2296239 Exon 8 chr20: 52775528
rs2274130 Intron 9 chr20: 52774601
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Gene SNP Exon/intron
‡ Position (bp)
rs1570670 Intron 9 chr20: 52774579
rs1977297 Intron 9 chr20: 52774479
rs1570669* Intron 9 chr20: 52774427
rs927650* Intron 11 chr20: 52772741
rs2762934* 30UTR chr20: 52771261
rs4809957 30UTR chr20: 52771171
rs6022987 30UTR chr20: 52770596
rs11907350 30UTR chr 20: 52770439
rs10623012 30UTR chr20: 52770055-52770054
rs4811494 30UTR chr20: 52769984
rs2762933 30UTR chr20: 52769903
rs6097807* 30UTR chr20: 52769455
rs6068810* 30UTR chr20: 52769351
Abbreviations: chr, chromosomes; UTR, untranslated region; SNP, single nucleotide polymorphism.
†SNP chromosomal location according to Ensembl.
‡Exon/intron description based on largest transcript listed in Ensembl.
§rs2228570 was formerly rs10735810.
*SNPs investigated in the initial discovery cohort.
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